不同诊断标准下儿童急性不明谱系白血病的临床特点和预后分析

doi:10.7499/j.issn.1008-8830.2105004

摘要
图/表
参考文献(21)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (596 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探索不同诊断标准下儿童急性不明谱系白血病（acute leukemias of ambiguous lineage，ALAL）的临床特点和预后。方法回顾性收集2015年12月至2019年12月诊治的39例儿童ALAL的临床资料，其中34例接受治疗。根据世界卫生组织和欧洲白血病免疫学分型协作组ALAL的诊断标准，将患儿分为ALAL组（28例）和伴髓系表达组（11例）。分析比较两组患儿临床特点、治疗及预后的差异。结果 34例接受治疗的患儿3年无事件生存（event-free survival，EFS）率和总生存率分别为75%±9%和88%±6%。采用髓系方案、淋系方案、髓系方案诱导未缓解转淋系方案患儿的3年EFS率分别为33%±27%、78%±10%和100%±0%（P<0.05）。诱导治疗后微小残留病阴性的患儿3年EFS率高于阳性患儿（96%±4% vs 38%±28%，P<0.05）。ETV6-RUNX1阳性均在伴髓系表达组，BCR-ABL1阳性、MLL-r阳性、高白细胞（白细胞≥50×10⁹/L）均在ALAL组。伴髓系表达组和ALAL组的3年EFS率差异无统计学意义（100%±0% vs 66%±11%，P>0.05）。结论淋系方案治疗ALAL患儿的疗效优于髓系方案，诱导治疗后微小残留病阳性提示不良预后。伴髓系表达的患儿未合并高白细胞和不良遗传学改变，预后好，提示将其按ALAL诊断和治疗时需尤为谨慎。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	高惠琴
	管贤敏
	温贤浩
	沈亚莉
	郭玉霞
	窦颖
	孟岩
	于洁

关键词 ：急性不明谱系白血病, 诊断标准, 预后, 儿童

Abstract：Objective To study the clinical features and prognosis of children with acute leukemias of ambiguous lineage (ALAL) under different diagnostic criteria. Methods A retrospective analysis was performed on the medical data of 39 children with ALAL who were diagnosed and treated from December 2015 to December 2019. Among the 39 children, 34 received treatment. According to the diagnostic criteria for ALAL by World Health Organization and European Group for the Immunological Characterization of Leukemias, the 39 children were divided into two groups: ALAL group (n=28) and myeloid expression group (n=11). The clinical features, treatment, and prognosis were compared between the two groups. Results The 34 children receiving treatment had a 3-year event-free survival (EFS) rate of 75%±9% and an overall survival rate of 88%±6%. The children treated with acute myeloid leukemia (AML) protocol had a 3-year EFS rate of 33%±27%, those treated with acute lymphoblastic leukemia (ALL) protocol had a 3-year EFS rate of 78%±10%, and those who had no remission after induction with AML protocol and then received ALL protocol had a 3-year EFS rate of 100%±0% (P<0.05). The children with negative minimal residual disease (MRD) after induction therapy had a significantly higher 3-year EFS rate than those with positive MRD (96%±4% vs 38%±28%, P<0.05). Positive ETV6-RUNX1 was observed in the myeloid expression group, and positive BCR-ABL1, positive MLL-r, and hyperleukocytosis (white blood cell count ≥50×109/L) were observed in the ALAL group. There was no significant difference in the 3-year EFS rate between the myeloid expression and ALAL groups (100%±0% vs 66%±11%, P>0.05). Conclusions ALL protocol has a better clinical effect than AML protocol in children with ALAL, and positive MRD after induction therapy suggests poor prognosis. Hyperleukocytosis and adverse genetic changes are not observed in children with myeloid expression, and such children tend to have a good prognosis, suggesting that we should be cautious to take it as ALAL in diagnosis and treatment.

Key words： Acute leukemias of ambiguous lineage Diagnostic criteria Prognosis Child

收稿日期: 2021-05-05

通讯作者: 于洁，女，教授。Email：1808106657@qq.com。 E-mail: 1808106657@qq.com

作者简介: 高惠琴，女，硕士，住院医；

引用本文:

高惠琴,管贤敏,温贤浩等. 不同诊断标准下儿童急性不明谱系白血病的临床特点和预后分析[J]. 中国当代儿科杂志, 2021, 23(8): 835-840.

GAO Hui-Qin,GUAN Xian-Min,WEN Xian-Hao et al. Clinical features and prognosis of children with acute leukemias of ambiguous lineage under different diagnostic criteria[J]. CJCP, 2021, 23(8): 835-840.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2105004 或 http://www.zgddek.com/CN/Y2021/V23/I8/835

	1 Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues[M]. Lyon: IARC Press, 2001: 106-107.
	Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)[J]. Leukemia, 1995, 9(10):1783-1786. PMID:7564526.
	Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.
	Maruffi M, Sposto R, Oberley MJ, et al. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis[J]. Leukemia, 2018, 32(7): 1515-1528. DOI: 10.1038/s41375-018-0058-4. PMID: 29550836.PMCID: PMC7508489.
	Weinberg OK, Seetharam M, Ren L, et al. Mixed phenotype acute leukemia: a study of 61 cases using World Health Organization and European Group for the Immunological Classification of Leukaemias criteria[J]. Am J Clin Pathol, 2014, 142(6): 803-808. DOI: 10.1309/AJCPPVUPOTUVOIB5. PMID: 25389334.
	Pomerantz A, Rodriguez-Rodriguez S, Demichelis-Gomez R, et al. Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used[J]. Blood Res, 2016, 51(4): 233-241. DOI: 10.5045/br.2016.51.4.233. PMID: 28090485. PMCID: PMC5234234.
	Hrusak O, de Haas V, Stancikova J, et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia[J]. Blood, 2018, 132(3): 264-276. DOI: 10.1182/blood-2017-12-821363. PMID: 29720486.
	许凤玲, 管贤敏, 温贤浩, 等. 儿童急性淋巴细胞白血病化疗相关严重不良反应的临床分析[J]. 中国当代儿科杂志, 2020, 22(8): 828-833. DOI: 10.7499/j.issn.1008-8830.2003253. PMID: 32800028. PMCID: PMC7441514.
	9 杨脉. 2015-AML03方案治疗儿童急性髓细胞白血病91例结果分析[D]. 重庆: 重庆医科大学, 2019.
	10 秘营昌, 卞寿庚. 急性白血病[M]. 3版. 北京: 科学出版社, 2007: 131-133.
	11 Orgel E, Alexander TB, Wood B, et al. Efficacy of all therapy for WHO2016-defined mixed phenotype acute leukemia: a report from the Children's Oncology Group[J]. Blood, 2017, 130(Suppl_1): 883. DOI: 10.1182/blood.V130.Suppl_1.883.883.
	Al-Seraihy AS, Owaidah TM, Ayas M, et al. Clinical characteristics and outcome of children with biphenotypic acute leukemia[J]. Haematologica, 2009, 94(12): 1682-1690. DOI: 10.3324/haematol.2009.009282. PMID: 19713227. PMCID: PMC2791935.
	Rubnitz JE, Onciu M, Pounds S, et al. Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital[J]. Blood, 2009, 113(21): 5083-5089. DOI: 10.1182/blood-2008-10-187351. PMID: 19131545. PMCID: PMC2686179.
	Oberley MJ, Raikar SS, Wertheim GB, et al. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study[J]. Leukemia, 2020, 34(7): 1741-1750. DOI: 10.1038/s41375-020-0741-0. PMID: 32060402. PMCID: PMC7332384.
	15 Orgel E, Oberley M, Li SS, et al. Predictive value of minimal residual disease in WHO2016-defined mixed phenotype acute leukemia (MPAL)[J]. Blood, 2016, 128(22): 178. DOI: 10.1182/blood.V128.22.178.178.
	Gerr H, Zimmermann M, Schrappe M, et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations[J]. Br J Haematol, 2010, 149(1): 84-92. DOI: 10.1111/j.1365-2141.2009.08058.x. PMID: 20085575.
	17 Gao H, Liu Y, Zhang R, et al. Pediatric mixed phenotype acute leukemia—41 cases report[J]. Blood, 2012, 120(21): 4811. DOI: 10.11406/rinketsu.59.75.
	Qasrawi A, Ramlal R, Munker R, et al. Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome[J]. Am J Hematol, 2020, 95(9): 1015-1021. DOI: 10.1002/ajh.25873. PMID: 32419244.
	McGinnis E, Yang D, Au N, et al. Clinical and laboratory features associated with myeloperoxidase expression in pediatric B-lymphoblastic leukemia[J]. Cytometry B Clin Cytom, 2020. DOI: 10.1002/cyto.b.21966. PMID: 33048471. Epub ahead of print.
	Raikar SS, Park SI, Leong T, et al. Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival[J]. Blood, 2018, 131(5): 573-577. DOI: 10.1182/blood-2017-09-807602. PMID: 29223952.
	Oberley MJ, Li S, Orgel E, et al. Clinical significance of isolated myeloperoxidase expression in pediatric B-Lymphoblastic leukemia[J]. Am J Clin Pathol, 2017, 147(4): 374-381. DOI: 10.1093/ajcp/aqx021. PMID: 28340210.